Aref Asieh, Khodhal Mina, Rashidi Homeira, Farhangiyan Zahra, Bitaraf Saeid
Department of Internal Medicine, School of Medicine, Chronic Renal Failure Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Department of Internal Medicine, Golestan Hospital, Chronic Renal Failure Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
J Family Med Prim Care. 2022 Dec;11(12):7735-7742. doi: 10.4103/jfmpc.jfmpc_627_22. Epub 2023 Jan 17.
Proteinuria is a common complication in patients with type 2 diabetic nephropathy (DN). The aim of this study was to evaluate the anti-proteinuria effect of active vitamin D in patients with type 2 DN.
A double-blind randomized clinical trial study was conducted on 42 DN patients selected by convenience sampling method. After selecting patients based on inclusion criteria, they were randomly divided into control and intervention groups. Patients in the intervention group received 0.25 mg of active vitamin D per day for 12 weeks. The variables evaluated in the patients on the first day of the intervention included fasting blood sugar (FBS), calcium, phosphorus, creatinine, glomerular filtration rate (GFR), systolic and diastolic blood pressure, and proteinuria. These variables were also evaluated at the end of the first, second, and third month of intervention. Data were collected and analyzed in Statistical Package for Social Sciences software version 22.
Around 52.5% of the patients participating in this study were male and 47.5% were female. The mean age of the patients was 55.52 ± 6.58 years. The results of repeated measures analysis showed that active vitamin D significantly reduced proteinuria ( = 0.000) in patients in the intervention group. The changes in FBS ( = 0.235), calcium ( = 0.393), phosphorus ( = 0.694), creatinine ( = 0.232), GFR ( = 0.347), systolic blood pressure ( = 0.615), and diastolic blood pressure ( = 0.115) were not significant in patients in the intervention group.
Prescription of active vitamin D can significantly reduce the incidence of proteinuria in patients with DN.
蛋白尿是2型糖尿病肾病(DN)患者常见的并发症。本研究旨在评估活性维生素D对2型DN患者的抗蛋白尿作用。
采用便利抽样法对42例DN患者进行双盲随机临床试验研究。根据纳入标准选择患者后,将他们随机分为对照组和干预组。干预组患者每天服用0.25mg活性维生素D,持续12周。在干预第一天评估患者的变量包括空腹血糖(FBS)、钙、磷、肌酐、肾小球滤过率(GFR)、收缩压和舒张压以及蛋白尿。在干预的第一个月、第二个月和第三个月末也对这些变量进行评估。数据在社会科学统计软件包22版中收集和分析。
参与本研究的患者中约52.5%为男性,47.5%为女性。患者的平均年龄为55.52±6.58岁。重复测量分析结果显示,活性维生素D显著降低了干预组患者的蛋白尿(=0.000)。干预组患者的FBS(=0.235)、钙(=0.393)、磷(=0.694)、肌酐(=0.232)、GFR(=0.347)、收缩压(=0.615)和舒张压(=0.115)变化不显著。
活性维生素D的处方可显著降低DN患者蛋白尿的发生率。